On July 27, the Indonesia-China Healthcare and Biotechnology Investment Forum, co-sponsored by the Embassy of the Republic of Indonesia in China and the China Committee of the Indonesian Chamber of Commerce and Industry, was held in Chengdu.

QuidelOrtho Corporation, a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has entered into a software development partnership with BYG4lab®, a leading provider of middleware and data management solutions for laboratories, that intends to accelerate QuidelOrtho’s efforts to expand and strengthen informatics offerings across its portfolio of diagnostics platforms.

Alveo Technologies said on Tuesday that it has partnered with Germany's Fraunhofer Institute for Cell Therapy and Immunology IZI to develop molecular diagnostic tests for the veterinary space.

The US Food and Drug Administration (FDA) has granted approval for Lumos Diagnostics’ FebriDx rapid point-of-care (POC) test.

POCT industry started late in China, the overall market size is still small currently, and the penetration rate in hospitals and other terminal sites is low, so there is a huge potential development space. Qianzhan Institute predicts that from 2022-2027, the Chinese POCT market will rise by about 9% CAGR to about 18 billion yuan in 2027.

Rice University bioengineers said this week that they have demonstrated a low-cost, point-of-care DNA test for HPV infections that could make cervical cancer screening more accessible in low- and middle-income countries where the disease kills more than 300,000 women each year.

Point-of-care testing (POCT), also known as "bedside testing" or "near-patient testing," is a test performed near or at the patient's location that may result in a change in the patient's disposition.

The US Food and Drug Administration in May granted 510(k) clearances for tests and testing systems by Abbott, Hologic, and Becton Dickinson, among others.

Cue Health, a healthcare technology company, announces an industry breakthrough as the first company to receive De Novo authorization from the U.S. Food and Drug Administration (FDA) for its Cue COVID-19 Molecular Test, designed for both home and point-of-care use.

QuidelOrtho Corporation, a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the first quarter ended April 2, 2023.